Main glossary
Special | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
R |
---|
Rare diseaseThe EU defines a condition as 'rare' if it affects less than 1 in 2000 people. | |
RegistriesA collection of information about individuals. | |
ReimbursementFollowing regulatory approval, a reimbursement
body will decide whether the manufacturer will be paid the cost of the drug,
based on a cost-effectiveness calculation. In the UK, the National Institute
for Health and Care Excellence (NICE) decide whether a drug will be reimbursed,
i.e. whether the NHS will fund patients' treatments | |
RemissionThe reduction or disappearance of the signs and
symptoms of a disease | |
Research Ethics CommitteeGroups of professionals and service users who review the ethical considerations of research studies. | |
Restricted fundingFunding provided to a charitable organisation with restrictions around its use to a specific project. | |
S |
---|
Scenarios | |
Sensitive dataUnder General Data Protection Regulation (GDPR),
health data are considered sensitive data and are therefore subject to specific
processing conditions | |
Sensitivity analyses | |
ShelvedA drug for which development has been halted,
sometimes because tests are not successful, but often because pursuing them simply does not present a tangible business opportunity | |
Social networks